Loading...
Please wait, while we are loading the content...
Similar Documents
Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma
| Content Provider | MDPI |
|---|---|
| Author | Thomopoulos, Thomas P. Rosati, Margherita Terpos, Evangelos Stellas, Dimitris Hu, Xintao Karaliota, Sevasti Bouchla, Anthi Katagas, Ioannis Antoniadou, Anastasia Mentis, Andreas Papageorgiou, Sotirios G. Politou, Marianna Bear, Jenifer Donohue, Duncan Kotanidou, Anastasia Kalomenidis, Ioannis Korompoki, Eleni Burns, Robert Pagoni, Maria Grouzi, Elisavet Labropoulou, Stavroula Stamoulis, Kostantinos Bamias, Aristotelis Tsiodras, Sotirios Dimopoulos, Meletios-Athanasios Pavlakis, George N. Pappa, Vasiliki Felber, Barbara K. |
| Copyright Year | 2021 |
| Description | COVID-19 is an ongoing pandemic with high morbidity and mortality. Despite meticulous research, only dexamethasone has shown consistent mortality reduction. Convalescent plasma (CP) infusion might also develop into a safe and effective treatment modality on the basis of recent studies and meta-analyses; however, little is known regarding the kinetics of antibodies in CP recipients. To evaluate the kinetics, we followed 31 CP recipients longitudinally enrolled at a median of 3 days post symptom onset for changes in binding and neutralizing antibody titers and viral loads. Antibodies against the complete trimeric Spike protein and the receptor-binding domain (Spike-RBD), as well as against the complete Nucleocapsid protein and the RNA binding domain (N-RBD) were determined at baseline and weekly following CP infusion. Neutralizing antibody (pseudotype NAb) titers were determined at the same time points. Viral loads were determined semi-quantitatively by SARS-CoV-2 PCR. Patients with low humoral responses at entry showed a robust increase of antibodies to all SARS-CoV-2 proteins and Nab, reaching peak levels within 2 weeks. The rapid increase in binding and neutralizing antibodies was paralleled by a concomitant clearance of the virus within the same timeframe. Patients with high humoral responses at entry demonstrated low or no further increases; however, virus clearance followed the same trajectory as in patients with low antibody response at baseline. Together, the sequential immunological and virological analysis of this well-defined cohort of patients early in infection shows the presence of high levels of binding and neutralizing antibodies and potent clearance of the virus. |
| Starting Page | 1844 |
| e-ISSN | 19994915 |
| DOI | 10.3390/v13091844 |
| Journal | Viruses |
| Issue Number | 9 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-09-15 |
| Access Restriction | Open |
| Subject Keyword | Viruses Infectious Diseases Convalescent Plasma Sars-cov-2 Covid-19 Antibody Kinetics Neutralizing Antibodies Spike Nucleocapsid |
| Content Type | Text |
| Resource Type | Article |
